Amarbir S Gill, MD
Clinical Assistant Professor of Otolaryngology-Head and Neck Surgery
[email protected]

Available to mentor

Amarbir S Gill, MD
Clinical Assistant Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • Qualifications
    • Fellow
      University of Utah, Rhinology and Skull Base Surgery, 2022
    • Resident
      University of California, Davis, Otolaryngolgy, 2020
    • M.D.
      George Washington University, Washington D.C., 2015
    • B.S., Physiological Sciences
      University of California, Los Angeles, Los Angeles, 2011
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    I am a surgeon-scientist focused on developing targeted nanotherapeutic drug delivery systems for the upper airway to improve clinical outcomes in adults with chronic rhinosinusitis (CRS). During my otolaryngology residency, and, more recently, during a 2-year research focused fellowship at the University of Utah, I gained significant experience in patient-centered outcomes research within the field of CRS. I published over 40 papers focusing on CRS, and presented my findings nationally at biannual conferences over the last 3 years. During fellowship, I became acutely aware of the lack of innovation in medical management of CRS in the last 20 years. In part due to a strong collaboration between my fellowship director’s lab and drug delivery expert, Dr Ghandheri’s lab, I became passionate about identifying unique disease targets that could be targeted by nanotherapeutic technology to develop novel and more effective topical drug delivery systems. To this end, we published several papers assessing various targetable differences between disease and healthy sinonasal tissue, including a publication in Nanomedicine focusing on leveraging vascular dysregulation differences across these cohorts to improve drug tunability. Although my mentors were focused on optimizing systemic drug delivery, I became interested in improving topical delivery. At the end of fellowship, I characterized a novel sinonasal epithelial cell type previously only described in the Peyer’s patches of the human gut. This microfold cell has a unique apical membrane receptor known as glycoprotein 2 (GP2) receptor, which is utilized by the cell to bind and endocytose various antigens. The goal of the present proposal is to develop a targeted, nasal nanoparticle (NP) based drug delivery system that utilizes an anti-GP2 antibody conjugation to bind epithelial cell GP2 receptors and initiate endocytosis across the apical membrane. I aspire to become a national and international leader in targeted drug delivery within the upper airway and am fully committed to working with colleagues in otolaryngology, pulmonology, and drug delivery to improve outcomes for patients with CRS. From a clinical perspective, my goal is to continue to nurture a clinical practice focused on treating CRS, which, in turn, informs and inspires my translational basic science studies of sinonasal NP drug delivery. This K12 provides the critical training in advanced biochemical laboratory techniques, bioinformatics, and tenets of drug delivery necessary for comprehensively studying design and implementation of targeted drug delivery systems in upper airway disease.

    Recent Publications See All Publications
    • Journal Article
      Treatment Outcomes With Conservative Management of Frontal Sinus Outflow Tract Fractures.
      Dennis SK, Steele TO, Gill AS, Hwang JC, Sarhadi KS, Cheema KS, Aulakh SS, Wilson MD, Strong EB. Otolaryngol Head Neck Surg, 2023 Dec; 169 (6): 1455 - 1461. DOI:10.1002/ohn.468
      PMID: 37573490
    • Additional Scholarship
      4 Ways to Stop a Runny Nose that Actually Work: Easy ways to put the breakes on the sniffling
      Mulcahy L. 2023 Oct 31;
    • Journal Article
      The Impact of Surgical Posterior Nasal Nerve Cryoablation on Symptoms and Disease-Specific Quality of Life in Patients With Chronic Rhinitis.
      Virani FR, Wilson MD, Beliveau AM, Gill AS, Strong EB, Steele TO. Ear Nose Throat J, 2023 Oct; 102 (10): 654 - 660. DOI:10.1177/01455613211018576
      PMID: 34128402
    • Journal Article
      Management paradigms for chronic rhinosinusitis in individuals with asthma: An evidence-based review with recommendations.
      Gill AS, Alt JA, Detwiller KY, Rowan NR, Gray ST, Hellings PW, Joshi SR, Lee JT, Soler ZM, Tan BK, Taylor-Cousar JL, Wise SK, Wu TJ, Beswick DM. Int Forum Allergy Rhinol, 2023 Sep; 13 (9): 1758 - 1782. DOI:10.1002/alr.23130
      PMID: 36579899
    • Presentation
      Sinus Disease
      2023 Aug 25;
    • Presentation
      Sinus Disease
      2023 Aug 25;
    • Journal Article
      An eosinophil peroxidase activity assay accurately predicts eosinophilic chronic rhinosinusitis.
      Smith KA, Gill AS, Pollard CE, Sumsion JS, Saffari H, Ashby S, Witt BL, Shipman PA, Gabrielsen DA, Yim MT, Levy JM, Oakley GM, Orlandi RR, Gleich GJ, Alt JA, Pulsipher A. J Allergy Clin Immunol, 2023 Aug; 152 (2): 400 - 407. DOI:10.1016/j.jaci.2023.04.012
      PMID: 37148919
    • Journal Article
      Assessing Stakeholder Engagement for Outcomes-Based Research Among Patients With Chronic Rhinosinusitis and Asthma: A Survey-Based Investigation.
      Gill AS, Shipman P, Beswick DM, Howe H, Alt JA. Ann Otol Rhinol Laryngol, 2023 Aug; 132 (8): 926 - 929. DOI:10.1177/00034894221129329
      PMID: 36226327